These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 20981265)

  • 21. Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach.
    Ranganna K; Selvam C; Shivachar A; Yousefipour Z
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33147762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances in histone deacetylase targeted cancer therapy.
    Hoshino I; Matsubara H
    Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
    Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.
    Zafar SF; Nagaraju GP; El-Rayes B
    Expert Opin Ther Targets; 2012 Jul; 16(7):707-18. PubMed ID: 22621256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting Histone Deacetylases in Malignant Melanoma: A Future Therapeutic Agent or Just Great Expectations?
    Garmpis N; Damaskos C; Garmpi A; Dimitroulis D; Spartalis E; Margonis GA; Schizas D; Deskou I; Doula C; Magkouti E; Andreatos N; Antoniou EA; Nonni A; Kontzoglou K; Mantas D
    Anticancer Res; 2017 Oct; 37(10):5355-5362. PubMed ID: 28982843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.
    Sharma NL; Groselj B; Hamdy FC; Kiltie AE
    BJU Int; 2013 Apr; 111(4):537-42. PubMed ID: 23551441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HDACs and HDAC inhibitors in colon cancer.
    Mariadason JM
    Epigenetics; 2008; 3(1):28-37. PubMed ID: 18326939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia.
    Ceccacci E; Minucci S
    Br J Cancer; 2016 Mar; 114(6):605-11. PubMed ID: 26908329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cyclinB1/Cdk1 in pancreatic cancer cells.
    Feng W; Cai D; Zhang B; Lou G; Zou X
    Biomed Pharmacother; 2015 Aug; 74():257-64. PubMed ID: 26349994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53.
    Mrakovcic M; Bohner L; Hanisch M; Fröhlich LF
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.
    Mishra VK; Wegwitz F; Kosinsky RL; Sen M; Baumgartner R; Wulff T; Siveke JT; Schildhaus HU; Najafova Z; Kari V; Kohlhof H; Hessmann E; Johnsen SA
    Nucleic Acids Res; 2017 Jun; 45(11):6334-6349. PubMed ID: 28369619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibitors in the treatment of hematological malignancies.
    Petrella A; Fontanella B; Carratù A; Bizzarro V; Rodriquez M; Parente L
    Mini Rev Med Chem; 2011 Jun; 11(6):519-27. PubMed ID: 21561404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer.
    Botrugno OA; Santoro F; Minucci S
    Cancer Lett; 2009 Aug; 280(2):134-44. PubMed ID: 19345000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment.
    Schizas D; Mastoraki A; Naar L; Spartalis E; Tsilimigras DI; Karachaliou GS; Bagias G; Moris D
    World J Gastroenterol; 2018 Nov; 24(41):4635-4642. PubMed ID: 30416311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone deacetylase inhibitor based prodrugs.
    Fan W; Zhang L; Jiang Q; Song W; Yan F; Zhang L
    Eur J Med Chem; 2020 Oct; 203():112628. PubMed ID: 32679451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent progress in the development of histone deacetylase inhibitors as anti-cancer agents.
    Zhang L; Lei J; Shan Y; Yang H; Song M; Ma Y
    Mini Rev Med Chem; 2013 Dec; 13(14):1999-2013. PubMed ID: 24160707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Histone deacetylase inhibitors - molecular mechanisms of actions and clinical applications].
    Grabarska A; Dmoszyńska-Graniczka M; Nowosadzka E; Stepulak A
    Postepy Hig Med Dosw (Online); 2013 Aug; 67():722-35. PubMed ID: 24018438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone deacetylase inhibitors in cancer therapy. A review.
    Hrabeta J; Stiborova M; Adam V; Kizek R; Eckschlager T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Jun; 158(2):161-9. PubMed ID: 24263215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting histone deacetylase in thyroid cancer.
    Russo D; Durante C; Bulotta S; Puppin C; Puxeddu E; Filetti S; Damante G
    Expert Opin Ther Targets; 2013 Feb; 17(2):179-93. PubMed ID: 23234477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination Therapies Targeting HDAC and IKK in Solid Tumors.
    Vancurova I; Uddin MM; Zou Y; Vancura A
    Trends Pharmacol Sci; 2018 Mar; 39(3):295-306. PubMed ID: 29233541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.